

## Multiple System Atrophy: Role of Coenzyme Q10

D Mantle<sup>1</sup>, Nadia Turton<sup>2</sup> and IR Hargreaves<sup>3\*</sup>

### Abstract

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a variable combination of autonomic failure, Parkinsonism, and ataxia. There is currently no treatment available to halt or delay progression of this disorder. Biochemically, MSA is characterized by mitochondrial dysfunction, oxidative stress, and inflammation. In the present article we have therefore reviewed the potential role of coenzyme Q10 (CoQ10) in the pathogenesis and treatment of MSA, on the basis of its role in mitochondrial function, and its antioxidant and anti-inflammatory activities, as well as its reported depletion in blood and cerebellar tissue from MSA patients.

**Keywords:** Coenzyme Q10; Multiple system atrophy; Mitochondrial dysfunction; Oxidative stress.

### Introduction

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a variable combination of autonomic failure, Parkinsonism, and ataxia [1]. As a consequence of the latter, MSA patients often suffer from genitourinary dysfunction and orthostatic hypotension [2]. With regard to treatment, L-dopa replacement therapy in MSA patients is less effective than in patients with Parkinson's disease (PD) [3]; paroxetine, a selective serotonin reuptake inhibitor has been shown

to

provide some benefit in MSA patients [4]. There is currently no treatment to halt or delay the progression of MSA. The age of onset of MSA is typically around 55-60 years of age. MSA may be difficult to distinguish clinically from other disorders, particularly PD, especially in the early stages of the disease [5]. MSA is one of a group of disorders known as synucleinopathies, characterized by deposition of abnormal misfolded alpha-synuclein proteins in the central and

<sup>1</sup>FRSC FRCPATH, Medical Adviser, Pharma Nord (UK) Ltd, United Kingdom

<sup>2</sup>Nadia Turton, PhD student, Liverpool John Moores University, United Kingdom

<sup>3</sup>FRCPATH, Reader, Liverpool John Moores University, United Kingdom

\*Corresponding Author: IR Hargreaves, FRCPATH, Reader, Liverpool John Moores University, United Kingdom.

Received Date: 04-07-2022

Accepted Date: 04-18-2022

Published Date: 04-30-2022

Copyright© 2022 by Mantle D, et al. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

peripheral nervous system [6]. In PD, the abnormal alpha-synuclein is deposited in neurons, whilst in MSA it forms glial cytoplasmic inclusions in oligodendrocytes. Histologically, selective atrophy and neuronal loss in striatonigral and olivopontocerebellar brain regions underlie the subdivision of MSA into Parkinsonian (MSA-P) and a cerebellar phenotype (MSA-C) [7]. Biochemically, MSA is characterized by depletion of coenzyme Q10 (CoQ10), which has a key role in cellular energy production. In some populations, particularly East Asian [8], the deficiency in CoQ10 levels is in turn associated with abnormalities in the gene, COQ2 which encodes the enzyme, coenzyme-Q2-polyprenyltransferase which is involved in the synthesis of CoQ10 [9]. Notwithstanding the COQ2 phenotype, the reports of decreased plasma and cerebellum CoQ10 status in MSA patients indicate evidence of impaired COQ biosynthesis, which in turn may contribute to the pathogenesis of MSA via mitochondrial dysfunction, oxidative stress, and inflammation. In the present review, we have therefore reviewed the potential role of CoQ10 in the pathogenesis and treatment of MSA.

### Coenzyme Q10

CoQ10 is an isoprenoid molecule that is synthesised by most cells of the body apart from red blood cells as its synthesis requires the presence of mitochondria [10,11]. CoQ10 has a number of key functions cellular functions including its role as an electron carrier in the mitochondrial respiratory chain (MRC) as well as its role as a cellular antioxidant [10,11]. CoQ10 has also been shown to directly regulate the expression of

more than 100 genes, including a number involved in inflammation [12]. Most of the body's daily requirement for CoQ10 (estimated as 500mg) is provided via endogenous synthesis, with a relatively small proportion (5mg) obtained from the normal diet; optimal endogenous synthesis occurs at 20-25 years of age, followed by an ensuing decline, such that the production at 65-70 years is approximately 50% of that at 20-25 years [13,14]. The biosynthesis of CoQ10 is a complex multi-step process [15] for which mutations in at least 10 genes that encode enzymes in the CoQ10 biosynthetic pathway have been identified [11] which if impaired can result in deficit in endogenous CoQ10 status, process relevant to the pathogenesis of MSA as outlined in the following sections of this article. With regard to the importance of CoQ10 in MRC function and cellular energy supply, several lines of evidence point to impaired brain energy supply/mitochondrial dysfunction in MSA. These include the demonstration of reduced cerebral glucose metabolism in MSA patients via positron emission tomography [16], and reduced creatine phosphate levels/depleted cell energy metabolism quantified by phosphorus-31 nuclear magnetic resonance spectroscopy in MSA patients [17,18].

### CoQ10 depletion in MSA

A number of clinical studies have reported evidence of decreased CoQ10 levels in plasma, CSF (cerebrospinal fluid) or cerebellar tissues of MSA patients. As noted in the Introduction, a deficiency in CoQ10 levels may be associated with abnormalities in the COQ2 gene encoding the enzyme (coenzyme-Q2-polyprenyltransferase) involved in the

synthesis of CoQ<sub>10</sub>, although this is not the case for all MSA patients [19]. Abnormalities in genes encoding other enzymes in the CoQ<sub>10</sub> biosynthetic pathway have also been reported in some studies, including PDSS<sub>1</sub> (Decaprenyl-diphosphate synthase subunit 1), COQ<sub>5</sub> (methyltransferase), and COQ<sub>7</sub> (5-demethoxyubiquinone hydroxylase) [20]. Thus, in a series of 44 MSA patients, Mitsui et al [21] found a significant 30% decrease in the mean plasma CoQ<sub>10</sub> level of MSA patients compared to controls, regardless of patient COQ<sub>2</sub> genotype. Kasai et al [22] described a significant reduction in serum CoQ<sub>10</sub> levels, when related to cholesterol level (to account for the lipoprotein fraction of the blood), in 18 MSA patients (COQ<sub>2</sub> genotype not specified) compared to controls; the circulatory lipoproteins, LDL (low density lipoprotein) and VLDL (very low-density lipoprotein) cholesterol act as the main carriers for CoQ<sub>10</sub> in the blood. In a series of 40 patients with MSA (COQ<sub>2</sub> phenotype not specified), Du et al [23] found significantly reduced CoQ<sub>10</sub> levels in plasma compared to controls. Compta et al [24] reported also reported significantly reduced CoQ<sub>10</sub> levels in CSF samples from a series of 20 MSA patients (COQ<sub>2</sub> genotype not specified), compared to those in patients with related neurological disorders (PD, progressive supranuclear palsy) or controls. With regards to brain tissue, the cerebellum appears to be most affected by CoQ<sub>10</sub> depletion. It is of note that cerebellar ataxia is a characteristic of MSA, whilst levels of CoQ<sub>10</sub> in the human brain are reported to be lowest in the cerebellum, which may thus be selectively vulnerable to CoQ<sub>10</sub> deficiency. Barca et al [25] found CoQ<sub>10</sub> levels in post-mortem cerebellar tissue to be significantly decreased (by 40%) from a

cohort of 12 MSA patients (without COQ<sub>2</sub> mutations), compared to controls. Although none of the MSA patients had COQ<sub>2</sub> mutations, there were significant decrease in the protein levels of PDSS<sub>1</sub> and COQ<sub>5</sub> CoQ<sub>10</sub> biosynthetic enzymes. It is of note that CoQ<sub>10</sub> levels in both striatal and occipital cortical samples from these MSA patients were similar to the controls. Similarly, Schottlaender et al [26] reported a significant decrease in CoQ<sub>10</sub> levels in post-mortem cerebellum samples from a series of 20 MSA cases, compared to controls, although only by 3-5%. Hsaiao et al [20] found reduced levels of ATP, associated with reduced expression of the COQ<sub>2</sub> and COQ<sub>7</sub> CoQ<sub>10</sub> biosynthetic enzymes, in disease-affected brain areas (principally cerebellum, as well as putamen) of MSA patients. Evidence of decreased MRC complex II-III activity has also been reported in the white matter of postmortem MSA patient brain samples which is thought to reflect the deficit in cerebral CoQ<sub>10</sub> status reported in this condition since the activity of this enzyme is dependent upon the endogenous level of this isoprenoid [27]. In the absence of a COQ<sub>2</sub> mutation the cause of CoQ<sub>10</sub> deficiency reported in MSA patients is uncertain but it may result from oxidative stress induced catabolism of CoQ<sub>10</sub> or the impairment of the enzymes in the biosynthetic pathway of the isoprenoid [26,27]. It is also of note that neurons cultured from MSA patients show evidence of autophagic impairment, as indicated by increased basal autophagy, reduced autophagic flux and reduced activity of the lysosomal enzymes,  $\alpha$ -Mannosidase and  $\beta$ -Mannosidase [28]. Furthermore, that one of the functions of CoQ<sub>10</sub> is the maintenance of

normal lysosomal function via its role in maintaining the acidity of the organelle [29].

### **Effect of CoQ<sub>10</sub> supplementation in MSA**

Studies on supplementation of CoQ<sub>10</sub> in MSA have been restricted to work in cell culture, or single patient case studies. Using neuronal cells cultured from MSA patients with and without the COQ2 mutation, Nakamoto et al [30] identified cellular dysfunction attributable to reduced CoQ<sub>10</sub> levels, which were in part resolved via administration of exogenous CoQ<sub>10</sub>. In an MSA patient with the COQ2 mutation and in an advanced stage of the disease, Mitsui et al [31] reported high dose CoQ<sub>10</sub> supplementation (1200mg/day) improved brain energy metabolism (as measured by cerebral oxygen metabolic rate/positron emission tomography). There is a clear rationale for the involvement of CoQ<sub>10</sub> in the pathogenesis of MSA, and evidence from a number of clinical studies for depleted CoQ<sub>10</sub> levels in blood or brain tissue from MSA patients. To date there has been no randomised controlled trials of supplementary CoQ<sub>10</sub> in MSA, and this is now warranted. One issue which needs to be first resolved is the optimal formulation to enable supplementary CoQ<sub>10</sub> to cross blood-brain barrier and access the brain [32].

### **Safety of CoQ<sub>10</sub>**

The safety of CoQ<sub>10</sub> has been confirmed in more than 200 randomized controlled clinical studies reported in the peer-reviewed medical literature, as listed on Medline. In these studies, CoQ<sub>10</sub> supplementation has been used in the treatment of in a number of disorders with no serious adverse clinical effects being reported. However, very rarely,

individuals may experience mild gastrointestinal disturbance, although this is does not appear to be dose related [33]. The observed safe level (OSL) risk assessment method has indicated that the evidence of safety for CoQ<sub>10</sub> is very strong at doses of up to 1200 mg/day, although much higher levels have been used in some randomised controlled trials without adverse effects. Supplementation with CoQ<sub>10</sub> does not appear to affect the biosynthesis of endogenous CoQ<sub>10</sub> [33].


### **Importance of CoQ<sub>10</sub> supplement formulation**

Bioavailability is defined as the proportion of an ingested substance that is absorbable from the digestive tract into the bloodstream. The bioavailability of CoQ<sub>10</sub> is low, typically of the order of 5%; this is a consequence of its chemical structure, i.e., it is a lipid soluble molecule consisting of a benzoquinone ring and a side chain comprising ten isoprenoid units. The bioavailability of CoQ<sub>10</sub> is in turn subject to the formulation of the supplement [34]. Supplemental CoQ<sub>10</sub> is manufactured via a procedure in which CoQ<sub>10</sub> crystals in polymorphic form are obtained as an end product of a yeast fermentation process. Since the human digestive tract is not capable of absorbing CoQ<sub>10</sub> in polymorphic crystalline form, it is important that supplements are formulated such that the CoQ<sub>10</sub> polymorphic crystals are transformed (via a thermal recrystallisation process) into an acicular form, which in turn is more readily dispersed into single CoQ<sub>10</sub> molecules in the digestive tract for subsequent absorption. In the absence of such crystal transformation, the bioavailability of supplemental CoQ<sub>10</sub> in

normal subjects is reduced by 75% [34]. In addition, because food supplements are not subject to the same strict quality standards as prescription-type medicines, it is important that CoQ<sub>10</sub> supplements should be manufactured to pharmaceutical standards if they are to be used in clinical studies; furthermore, such CoQ<sub>10</sub> supplements should be of proven bioavailability in human subjects, as documented in the peer-reviewed medical literature. In this regard, to date there is only one CoQ<sub>10</sub> product (Myoquinon) that has received a marketing authorisation within the EU, for the adjuvant treatment of heart failure.

## Conclusion

MSA is a progressive neurodegenerative disorder for which there is relatively little available in terms of conventional treatment. There is evidence from a number of clinical studies for a depletion of CoQ<sub>10</sub> levels in relevant tissues from MSA patients (Figure 1), and there is a rationale for the involvement of CoQ<sub>10</sub> in the pathogenesis of this disorder, based on its role in cellular energy metabolism, and its antioxidant and anti-inflammatory action.



**Figure 1:** The potential causes of a CoQ<sub>10</sub> deficiency in multiple system atrophy and its contribution to disease pathophysiology. COQ<sub>10</sub>: Coenzyme Q<sub>10</sub>.

What is now required is a clinical study to investigate the potential benefit of supplementing CoQ<sub>10</sub> in MSA patients. On the UMINCTR clinical trials registry, a randomised controlled study to investigate the efficacy of CoQ<sub>10</sub> in MSA patients is listed

as being underway (UMIN000031771), under the direction of Professor S. Tsuji of University of Tokyo Hospital, but no other information is currently available: ([https://center6.umin.ac.jp/cgi-open-bin/ctr\\_e/ctr\\_view.cgi?recptno=R000036134](https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036134))

## References

- Chelban V, Catereniuc D, Aftene D, Gasnas A, Vichayanrat E, Iodice V, et al. An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention. *J Neurol*. 2020;267(9):2754-70. [PubMed](#) | [CrossRef](#)
- Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation?. *J Neurol Neurosurg Psychiatry*. 2000;68(1):65-9. [PubMed](#) | [CrossRef](#)
- Mészáros L, Hoffmann A, Wihan J, Winkler J. Current symptomatic and disease-modifying treatments in multiple system atrophy. *Int J Mol Sci*. 2020;21(8):2775. [PubMed](#) | [CrossRef](#)
- Coon EA, Ahlskog JE, Silber MH, Fealey RD, Benarroch EE, Sandroni P, et al. Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?. *Park Relat Disord*. 2018;48:51-3. [PubMed](#) | [CrossRef](#)
- Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. *Auton Neurosci*. 2018;211:15-25. [PubMed](#) | [CrossRef](#)
- Coon EA, Singer W. Synucleinopathies. *Continuum (Minneapolis, Minn.)*. 2020;26(1):72. [PubMed](#) | [CrossRef](#)
- Roncevic D, Palma JA, Martinez J, Goulding N, Norcliffe-Kaufmann L, Kaufmann H. Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival. *J Neural Transm*. 2014;121(5):507-12. [PubMed](#) | [CrossRef](#)
- Zhao Q, Yang X, Tian S, An R, Zheng J, Xu Y. Association of the COQ2 V393A variant with risk of multiple system atrophy in East Asians: a case-control study and meta-analysis of the literature. *Neurol Sci*. 2016;37(3):423-30. [PubMed](#) | [CrossRef](#)
- Stefely JA, Pagliarini DJ. Biochemistry of mitochondrial coenzyme Q biosynthesis. *Trends Biochem Sci*. 2017;42(10):824-43. [PubMed](#) | [CrossRef](#)
- Crane FL. Biochemical functions of coenzyme Q<sub>10</sub>. *J Am Coll Nutr*. 2001;20(6):591-8. [PubMed](#) | [CrossRef](#)
- Hargreaves I, Heaton RA, Mantle D. Disorders of human coenzyme q<sub>10</sub> metabolism: An overview. *Int J Mol Sci*. 2020;21(18):6695. [PubMed](#) | [CrossRef](#)
- Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F. Functions of coenzyme Q<sub>10</sub> in inflammation and gene expression. *Biofactors*. 2008;32(1-4):179-83. [PubMed](#) | [CrossRef](#)
- Kalén A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. *Lipids*. 1989;24(7):579-84. [PubMed](#) | [CrossRef](#)
- Weber C, Bysted A, Hllmer G. The coenzyme Q<sub>10</sub> content of the average Danish diet. *International Journal for Vitamin and Nutrition research. Internationale Zeitschrift für Vitamin-und Ernährungsforschung. Int J Vitam Nutr Res*. 1997 Jan 1;67(2):123-9. [PubMed](#) | [CrossRef](#)
- Bentinger M, Tekle M, Dallner G. Coenzyme Q-biosynthesis and functions. *Biochemical and biophysical research communications*. 2010;396(1):74-9. [PubMed](#) | [CrossRef](#)
- Feng T, Wang Y, Ouyang Q, Duan Z, Li W, Lu L, et al. Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease. *Neurol Res*. 2008;30(4):377-82. [PubMed](#) | [CrossRef](#)
- Martinelli P, Giuliani S, Lodi R, Iotti S, Zaniol P, Barbiroli B. Failure of brain and skeletal muscle energy metabolism in multiple system atrophy shown by in vivo phosphorous MR spectroscopy. *Adv Neurol*. 1996;69:271-7. [PubMed](#)

18. Barbiroli B, Martinelli P, Patuelli A, Lodi R, Iotti S, Cortelli P, et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. *Mov Disord: official journal of the Movement Disorder Society*. 1999;14(3):430-5. [PubMed](#) | [CrossRef](#)
19. Porto KJ, Hirano M, Mitsui J, Chikada A, Matsukawa T, Ishiura H, et al. Japan Multiple System Atrophy Registry Consortium. COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. *J Neurol Sci*. 2021;429:117623. [PubMed](#) | [CrossRef](#)
20. Hsiao JH, Purushothuman S, Jensen PH, Halliday GM, Kim WS. Reductions in COQ2 expression relate to reduced ATP levels in multiple system atrophy brain. *Front Neurosci*. 2019;1187. [PubMed](#) | [CrossRef](#)
21. Mitsui J, Matsukawa T, Yasuda T, Ishiura H, Tsuji S. Plasma coenzyme Q10 levels in patients with multiple system atrophy. *JAMA Neurol*. 2016;73(8):977-80. [PubMed](#) | [CrossRef](#)
22. Kasai T, Tokuda T, Ohmichi T, Ishii R, Tatebe H, Nakagawa M, et al. Serum levels of coenzyme Q10 in patients with multiple system atrophy. *PLoS One*. 2016;11(1):e0147574. [PubMed](#) | [CrossRef](#)
23. Du J, Wang T, Huang P, Cui S, Gao C, Lin Y, et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. *Park Relat Disord*. 2018;57:58-62. [PubMed](#) | [CrossRef](#)
24. Compta Y, Giraldo DM, Munoz E, Antonelli F, Fernández M, Bravo P, et al. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. *Park Relat Disord*. 2018;46:16-23. [PubMed](#) | [CrossRef](#)
25. Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. *J Neuropathol Exp Neurol*. 2016;75(7):663-72. [PubMed](#) | [CrossRef](#)
26. Schottlaender LV, Bettencourt C, Kiely AP, Chalasani A, Neergheen V, Holton JL, et al. Coenzyme Q10 levels are decreased in the cerebellum of multiple-system atrophy patients. *PLoS One*. 2016;11(2):e0149557. [PubMed](#) | [CrossRef](#)
27. Foti SC, Hargreaves I, Carrington S, Kiely AP, Houlden H, Holton JL. Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson's disease. *Sci Rep*. 2019;9(1):1-2. [PubMed](#) | [CrossRef](#)
28. Compagnoni GM, Di Fonzo A. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. *Acta Neuropathol Commun*. 2019;7(1):1-2. [PubMed](#) | [CrossRef](#)
29. Heaton RA, Heales S, Rahman K, Sexton DW, Hargreaves I. The effect of cellular coenzyme Q10 deficiency on lysosomal acidification. *J Clin Med*. 2020;9(6):1923. [PubMed](#) | [CrossRef](#)
30. Nakamoto FK, Okamoto S, Mitsui J, Sone T, Ishikawa M, Yamamoto Y, et al. The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. *Sci Rep*. 2018;8(1):1-3. [PubMed](#) | [CrossRef](#)
31. Mitsui J, Koguchi K, Momose T, Takahashi M, Matsukawa T, Yasuda T, et al. Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations. *Cerebellum*. 2017;16(3):664-72. [PubMed](#) | [CrossRef](#)
32. Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10, Ageing and the Nervous System: An Overview. *Antioxidants*. 2021;11(1):2. [PubMed](#) | [CrossRef](#)
33. Hidaka T, Fujii K, Funahashi I, Fukutomi N, Hosoe K. Safety assessment of coenzyme Q10 (CoQ10). *Biofactors*. 2008;32(1-4):199-208. [PubMed](#) | [CrossRef](#)
34. López-Lluch G, del Pozo-Cruz J, Sánchez-Cuesta A, Cortés-Rodríguez AB, Navas P. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. *Nutrition*. 2019;57:133-40. [PubMed](#) | [CrossRef](#)